Therapeutic manipulation of the collateral circulation - Future

Coronary Artery Disease

Volumn 15, Issue 7, 2004, Pages 399-403

  Van Royen, Niels ^a,b   Piek, Jan J ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Angiogenesis; Arteriogenesis; Collateral circulation; Coronary artery disease; Granulocyte macrophage colony stimulating factor; Growth factors; Monocyte chemo attractant protein 1; Monocytes; Transforming growth factor 1

Indexed keywords

ENOXAPARIN; HEPARIN; MONOCYTE CHEMOTACTIC PROTEIN 1; RECOMBINANT FIBROBLAST GROWTH FACTOR; RECOMBINANT FIBROBLAST GROWTH FACTOR 1; RECOMBINANT FIBROBLAST GROWTH FACTOR 2; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT GROWTH FACTOR; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA1; RECOMBINANT VASCULOTROPIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANGIOGENESIS; ATHEROGENESIS; ATHEROSCLEROSIS; CLINICAL TRIAL; COLLATERAL CIRCULATION; CORONARY ARTERY; CORONARY ARTERY DISEASE; HUMAN; KINESIOTHERAPY; PRIORITY JOURNAL; REVIEW;

ARTERIAL OCCLUSIVE DISEASES; COLLATERAL CIRCULATION; FORECASTING; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC;

EID: 8544230667     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-200411000-00006     Document Type: Review

References (41)

1. Fulton WFM. The coronary arteries-arteriography, microanatomy and pathogenesis of obliterative coronary artery disease. Springfield, IL: Charles C. Thomas; 1965.
2. Schaper W, De Brabander M, Lewi P. DNA synthesis and mitoses in coronary collateral vessels of the dog. Circ Res 1971; 28:671-679.
3. Schaper J, Konig R, Franz D, Schaper W. The endothelial surface of growing coronary collateral arteries. Intimal margination and diapedesis of monocytes. A combined SEM and TEM study. Virchows Arch A Pathol Anat Histol 1976; 370:193-205.
4. Fujita M, Sasayama S, Asanoi H, Nakajima H, Sakai O, Ohno A. Improvement of treadmill capacity and collateral circulation as a result of exercise with heparin pretreatment in patients with effort angina. Circulation 1988; 77:1022-1029.
5. Fujita M, Sasayama S, Kato K, Takaori S. Prospective, randomized, placebo-controlled, double-blind, multicenter study of exercise with enoxaparin pretreatment for stable-effort angina. Am Heart J 1995; 129:535-541.
6. Schumacher B, Pecher P, von Specht BU, Stegmann T. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation 1998; 97:645-650.
7. Losordo DW, Vale PR, Symes JF, Dunnington CH, Esakof DD, Maysky M, et al. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 1998; 98:2800-2804.
8. Baumgartner I, Pieczek A, Manor O, Blair R, Kearney M, Walsh K, et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998; 97:1114-1123.
9. Hendel RC, Henry TD, Rocha-Singh K, Isner JM, Kereiakes DJ, Giordano FJ, et al. Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose-dependent effect. Circulation 2000; 101:118-121.
10. Sellke FW, Laham RJ, Edelman ER, Pearlman JD, Simons M. Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results. Ann Thorac Surg 1998; 65:1540-1544.
11. Udelson JE, Dilsizian V, Laham RJ, Chronos N, Vansant J, Blais M, et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 improves stress and rest myocardial perfusion abnormalities in patients with severe symptomatic chronic coronary artery disease. Circulation 2000; 102:1605-1610.
12. Simons M, Annex BH, Laham RJ, Kleiman N, Henry T, Dauerman H, et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 2002; 105:788-793.
13. Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ, et al. The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation 2003; 107:1359-1365.
14. Rajagopalan S, Mohler ER, 3rd, Lederman PJ, Mendelsohn FO, Saucedo JF, Goldman CK, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003; 108:1933-1938.
15. Deindl E, Buschmann I, Hoefer IE, Podzuwert T, Boengler K, Vogel S, et al. Role of ischemia and of hypoxia-inducible genes in arteriogenesis after femoral artery occlusion in the rabbit. Circ Res 2001; 89:779-786.
16. Hershey JC, Baskin E.P.B, Glass JD, Hartman HA, Gilberto DB, Rogers IT, et al. Revascularization in the rabbit hindlimb: dissociation between capillary sprouting and arteriogenesis. Cardiovasc Res 2001; 49:618-625.
17. Masaki I, Yonemitsu Y, Yamashita A, Sata S, Tanii M, Komori K, et al. Angiogenic gene therapy for experimental critical limb ischemia: acceleration of limb loss by overexpression of vascular endothelial growth factor 165 but not of fibroblast growth factor-2. Circ Res 2002; 90: 966-973.
18. Lederman RJ, Mendelsohn FO, Anderson RD, Saucedo JF, Tenaglia AN, Hermiller JB, et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet 2002; 359:2053-2038.
19. Grines CL, Watkins MW, Helmer G, Penny W, Brinker J, Marmur JD, et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002; 105:1291-1297.
20. Grines CL, Watkins MW, Mahmarian JJ, Iskandrian AE, Rade JJ, Marrott P, et al. A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J Am Coll Cardiol 2003; 42:1339-1347.
21. Ito WD, Arras M, Winkler B, Scholz D, Schaper J, Schaper W, et al. Monocyte chemotactic protein-1 increases collateral and peripheral conductance after femoral artery occlusion. Circ Res 1997; 80: 829-837.
22. Buschmann IR, Hoefer IE, van Royen N, Katzer E, Braun-Dulleaus R, Heil M, et al. GM-CSF: a strong arteriogenic factor acting by amplification of monocyte function. Atherosclerosis 2001; 159:343-356.
23. van Royen N, Hoefer I, Buschmann I, Heil M, Kostin S, Deindl E, et al. Exogenous application of transforming growth factor beta 1 stimulates arteriogenesis in the peripheral circulation. FASEB J 2002; 16: 432-434.
24. Boengler K, Pipp F, Fernandez B, Ziegelhoeffer T, Schaper W, Deindl E, et al. Arteriogenesis is associated with an induction of the cardiac ankyrin repeat protein (carp). Cardiovasc Res 2003; 59:573-581.
25. Seiler C, Pohl T, Wustmann K, Hutter D, Nicolet P-A, Windecker S, et al. Promotion of collateral growth by granulocyte-macrophage colony-stimulating factor in patients with coronary artery disease: a randomized, double-blind, placebo-controlled study. Circulation 2001; 104: 2012-2017.
26. van Royen N, Piek JJ, Legemate DA, Schaper W, Oskam J, Atasever B, et al. Design of the START-trial: STimulation of ARTeriogenesis using subcutaneous application of GM-CSF as a new treatment for peripheral vascular disease. A randomized, double-blind, placebo-controlled trial. Divergent effects of GM-CSF and TGFbeta1 on bone marrow-derived macrophage arginase-1 activity, MCP-1 expression, and matrix metalloproteinase-12: a potential role during arteriogenesis. Vasc Med 2003; 8:191-196.
27. Tateishi-Yuyama E, Matsubara H, Murohara T, Ikeda U, Shintani S, Masaki H, et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet 2002; 360:427-435.
28. Strauer BE, Brehm M, Zeus T, Kostering M, Hernandez A, Sorg RV, et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 2002; 106: 1913-1918.
29. Assmus B, Schachinger V, Teupe C, Britten M, Lehmann R, Dobert N, et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation 2002; 106:3009-3017.
30. Feldman RL, Pepine CJ. Evaluation of coronary collateral circulation in conscious humans. Am J Cardiol 1984; 53:1233-1238.
31. Rentrop KP, Cohen M, Blanke H, Phillips RA. Changes in collateral channel filling immediately after controlled coronary artery occlusion by an angioplasty balloon in human subjects. J Am Coll Cardiol 1985; 5: 587-592.
32. Cohen M, Rentrop KP. Limitation of myocardial ischemia by collateral circulation during sudden controlled coronary artery occlusion in human subjects: a prospective study. Circulation 1986; 74:469-476.
33. Seiler C, Fleisch M, Garachemani A, Meier B. Coronary collateral quantitation in patients with coronary artery disease using intravascular flow velocity or pressure measurements. J Am Coll Cardiol 1998; 32: 1272-1279.
34. Werner GS, Ferrari M, Betge S, Gastmann O, Richartz BM, Figulla HR. Collateral function in chronic total coronary occlusions is related to regional myocardial function and duration of occlusion. Circulation 2001; 104:2784-2790.
35. Piek JJ, van Liebergen RA, Koch KT, Peters RJ, David GK. Comparison of collateral vascular responses in the donor and recipient coronary artery during transient coronary occlusion assessed by intracoronary blood flow velocity analysis in patients. J Am Coll Cardiol 1997; 29:1528-1535.
36. Piek JJ, van Liebergen RA, Koch KT, Peters RJ, David GK. Clinical, angiographic and hemodynamic predictors of recruitable collateral flow assessed during balloon angioplasty coronary occlusion. J Am Coll Cardiol 1997; 29:275-282.
37. Barger AC, Beeuwkes Rd, Lainey LL, Silverman KJ. Hypothesis: vasa vasorum and neovascularization of human coronary arteries. A possible role in the pathophysiology of atherosclerosis. N Engl J Med 1984; 310: 175-177.
38. Moulton KS, Heller E, Konerding MA, Flynn E, Palinski W, Folkman J, et al. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation 1999; 99:1726-1732.
39. Celletti FL, Waugh JM, Amabile PG, Brendolan A, Hilfiker PR, Dake MD. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 2001; 7:425-429.
40. Celletti FL, Hilfiker PR, Ghafouri P, Dake MD. Effect of human recombinant vascular endothelial growth factor165 on progression of atherosclerotic plaque. J Am Coll Cardiol 2001; 37:2126-2130.
41. van Royen N, Hoefer I, Bottinger M, Hua J, Grundmann S, Voskuil M, et al. Local monocyte chemoattractant protein-1 therapy increases collateral artery formation in apolipoprotein E-deficient mice but induces systemic monocytic CD11b expression, neointimal formation, and plaque progression. Circ Res 2003; 92:218-225.